About I-MOVE‎ > ‎

Project background

I-MOVE network

            The network started in 2007 with funding from the European Centre for Disease Prevention and Control (ECDC).
            It is coordinated by EpiConcept

To measure influenza vaccine effectiveness in each of the influenza seasons. 

Having annual influenza VE estimates at European level as soon as possible after the start of a seasonal influenza epidemic or a pandemic and monitoring it along the course of the epidemic/pandemic is essential to:
  • decide on recommendations for the use of the vaccine,
  • target complementary or alternative public health measures (e.g. antivirals) for population sub-groups in which vaccine is less effective,
  • allow more precise estimates of the impact of current vaccination strategies on the burden of disease to support vaccination campaigns,
  • trigger further investigations on seasonal and pandemic vaccines (improve composition, use of adjuvants, need for booster doses),
  • better manage and respond to expected reports of vaccine failures (especially during a pandemic),
  • counter-balance reports of adverse events following immunisation by providing elements for an adequate risk management and cost-effectiveness analysis.

The network  is co-funded by ECDC, and Member states. WHO contributes to the funding of the Romania study site.

In 2016-17, studies are conducted i
      • Case control studies using a test-negative design in France, Germany, Hungary, Ireland, Italy, the Netherlands, Poland, Portugal, Romania, Spain, Sweden
      • Chort studies in England & Wales, the Navarra region of Spain, Scotland, Finland

Esther Kissling,
18 Mar 2009, 07:14